icad inc. (ICAD) Scheduled to Post Earnings on Wednesday
icad inc. (NASDAQ:ICAD) last issued its quarterly earnings results on Tuesday, August 8th. The technology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. icad inc. had a negative net margin of 34.74% and a negative return on equity of 44.39%. The firm had revenue of $6.41 million during the quarter, compared to the consensus estimate of $6.41 million. On average, analysts expect icad inc. to post $-0.51 EPS for the current fiscal year and $-0.25 EPS for the next fiscal year.
Several equities analysts have commented on ICAD shares. Laidlaw reiterated a “buy” rating and issued a $11.00 price objective on shares of icad inc. in a report on Tuesday, July 25th. ValuEngine downgraded shares of icad inc. from a “sell” rating to a “strong sell” rating in a report on Thursday, September 7th.
In related news, Director Dr Lawrence Howard acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were purchased at an average cost of $3.33 per share, for a total transaction of $33,300.00. Following the completion of the acquisition, the director now directly owns 488,022 shares in the company, valued at $1,625,113.26. The purchase was disclosed in a filing with the SEC, which is available at this link. 19.20% of the stock is owned by insiders.
An institutional investor recently raised its position in icad inc. stock. Vanguard Group Inc. grew its holdings in icad inc. (NASDAQ:ICAD) by 0.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 456,377 shares of the technology company’s stock after acquiring an additional 2,007 shares during the quarter. Vanguard Group Inc. owned 2.79% of icad inc. worth $1,912,000 as of its most recent SEC filing. Institutional investors and hedge funds own 23.98% of the company’s stock.
icad inc. Company Profile
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with MarketBeat.com's FREE daily email newsletter.